Artica Therapeutics is focusing on the development of small molecule medicines to treat diseases of high unmet medical need, e.g. inflammatory diseases. The company has developed specific expertise to target so-called G protein-coupled receptors (GPCRs), which were previously difficult to target for drug development.

To equip the R&D facilities at the Leiden Bio Science Park, the company has successfully applied for a Mibiton lease funding.